Determination of the Interday and Intraday Reliability of Serum Cartilage Oligomeric Matrix Protein in a Physically Active Population

Johanna M. Hoch¹, Carl G. Mattacola¹, Jennifer M. Medina-McKeon¹, Jay N. Shah², and Christian Lattermann²

Abstract

Objective: To determine the intraday and interday reliability of serum cartilage oligomeric matrix protein (sCOMP) in a physically active population with no history of lower extremity surgery. Design: A repeated-measures reliability study was employed to determine the intraday and interday reliability of sCOMP in a physically active cohort. A total of 23 subjects were recruited to the laboratory on 3 separate occasions for nonfasting serum collection. Subjects had no history of lower extremity surgery and were free from acute injury within the last 3 months. Results: Our results indicate strong reliability for both intraday intraclass correlation coefficient (ICC) (0.76) and interday ICC (0.74) sCOMP values. Conclusion: Our results demonstrate that following 30 minutes of inactivity, nonfasting serum samples remain stable over the course of 1 day and between 2 consecutive days in a healthy population with no history of lower extremity surgery. Future research studies are needed to further investigate the magnitude of change in this biomarker for patients with acute articular cartilage damage to determine its appropriateness for use in this population and for varying degrees of articular cartilage severity.

Keywords

articular cartilage, biomarkers, knee injury

Introduction

Serum cartilage oligomeric matrix protein (sCOMP) is a noncollagenous protein primarily identified in articular cartilage.¹⁻³ Elevated levels of this biomarker have been identified in patients suffering from knee osteoarthritis (OA), a chronic articular cartilage degradation disease, when compared to healthy controls.⁴⁻¹⁰ In addition, elevations of this biomarker have been documented in patients who sustained acute knee ligament injury, such as anterior cruciate ligament (ACL) rupture.¹¹⁻¹³ The basic assumption is that these elevations are associated with articular cartilage damage, not ligament injury. However, documentation of concomitant injuries, such as bone bruise lesions and associated articular cartilage injury, was not reported in these studies.¹¹⁻¹³

An estimated 80% of MRI-confirmed ACL ruptures have documented concomitant bone bruise lesions.¹⁴⁻¹⁷ Often, these lesions are not associated with visible articular cartilage injury at the time of MRI and surgical intervention.¹⁸,¹⁹ However, biopsies of the overlying articular cartilage indicate degeneration of the chondrocytes and substantial damage to the superficial matrix.²⁰,²¹ Therefore, sCOMP may be a useful biomarker to better understand the articular cartilage damage that is associated with bone bruise lesions for patients who suffer acute knee injury.

In order to further investigate the utility of sCOMP as a biomarker for acute articular cartilage damage, the reliability of this measure must be documented. Determination of interday and intraday reliability measures is necessary to ensure this marker is clinically applicable for future research studies. The purpose of this study was to determine the interday and intraday reliability of sCOMP in a healthy, physically active cohort.

¹Department of Rehabilitation Sciences, University of Kentucky, Lexington, KY, USA
²Department of Orthopaedic Surgery and Sports Medicine, University of Kentucky, Lexington, KY, USA

Corresponding Author:
Johanna M. Hoch, Department of Rehabilitation Sciences, University of Kentucky, 900 South Limestone, Charles Webbington Building, Lexington, KY 40536
Email: johanna.clark@uky.edu
Methods

Design
A repeated-measures reliability design was employed for this study. The independent variable was time (time 1 = T1, time 2 = T2, and time 3 = T3), and the dependent variable was sCOMP.

Population
A sample of 23 physically active subjects (4 males and 19 females; age: 27.2 ± 3.8 years; height: 168.6 ± 6.3 cm; mass: 150.6 ± 31.4 kg) volunteered to participate. Subjects were included if they had no history of lower extremity surgery and no history of lower extremity injury within the past 3 months. Subjects were considered physically active if they scored a 6 or higher on the NASA Physical Activity Status Scale. A score of 6 represents heavy aerobic exercise in the form of either running 6 to 10 miles a week or walking 7 to 13 miles per week. Subjects maintained their usual daily activities while participating, and hourly documentation logs were collected while the subjects were enrolled. This study was approved by the University of Kentucky Institutional Review Board, and approved informed consent was obtained from the subjects prior to participation in our study.

Procedure
A total of 3 serum collections were performed on 2 separate days. Subjects reported for serum collection on 2 separate days and 3 different time points. To determine the intraday (within-day) reliability, subjects reported to the laboratory once in the morning (T1) and approximately 7 hours later on the same day (T2). To determine interday reliability (between days), subjects reported to the laboratory the morning after (24 hours) the first draw (T3).

Upon arrival, each subject was asked to remain seated at a table for 30 minutes prior to data collection based on the recommendations of Andersson et al. and Mundermann et al. Following 30 minutes of rest, a maximum of 10 mL of blood was collected from the antecubital vein in a red-top safety tube following standard operating procedures for venipuncture.

Enzyme-Linked Immunosorbent Assay
Immediately after serum collection, the blood was placed on ice and transported for separation. After clotting for 30 minutes at room temperature, sera were separated in a refrigerated centrifuge at 4 °C at 2000g for 15 minutes, placed in labeled aliquots, and stored in a −80 °C freezer. Once all samples were collected, sCOMP concentrations were determined using a commercially available, competitive enzyme-linked immunosorbent assay (ELISA) kit (cat. no. COMP200, Wieslab hCOMP quantitative kit, IBL Euro-Diagnostica, Malmo, Sweden). This ELISA kit utilized a rabbit polyclonal antiserum directed to human COMP, and the standard curve was determined using native human articular cartilage COMP (Wieslab hCOMP quantitative kit, IBL Euro-Diagnostica). Serum COMP values are expressed as ng/mL. The average intra-assay coefficient of variance (CV) of all controls was 2.8%, the average interassay CV of all controls was 2.1%, and the average CV of all samples was 2.5%.

Statistical Analysis
Descriptive statistics (means ± standard deviations) for each test session were calculated. Intraday and interday reliabilities were estimated using intraclass correlation coefficients (ICCs). A total of 23 participants’ data were used to calculate intraday reliability (T1 v. T2). A total of 20 participants’ data were used to calculate interday reliability (T1 v. T3). Standard error of measurement (SEM) was also calculated for each correlation. ICCs were interpreted as weak if they were less than 0.40, they were moderate if between 0.41 and 0.69, and values of more than 0.70 were interpreted as strong. Within-day and between-day minimal detectable change (MDC) values were also calculated using the interday and intraday reliability and SEM data collected during each session. MDC values were calculated at the 95% confidence interval using the formula SEM * 1.96 * √2. All statistical analyses were performed using PWAS software, version 18.0 (Somers, NY).

Results
The mean sCOMP value for T1 was 1287.44 (±205.70) ng/mL, for T2 was 1292.90 (±228.00) ng/mL, and for T3 was 1270.15 (±213.60) ng/mL. ICCs, SEMs, 95% confidence intervals (CIs), and MDC values for each of the testing sessions are presented in Table 1. The ICCs for the interday (0.76) and intraday (0.74) were both interpreted as strong.

Discussion
To our knowledge, we were the first to document the interday and intraday reliability of sCOMP in a healthy, physically active cohort with no history of lower extremity surgery or acute lower extremity injury within the last 3 months. The
results of our investigation indicate strong interday and intraday reliability for sCOMP in a young, physically active cohort. To provide a more comprehensive interpretation of our reliability values, we have compared our findings to those that have been previously published.

Several studies have reported temporal patterns for sCOMP. For example, Vilim et al.28 conducted a study to verify their ELISA was sensitive to changes over time in sCOMP in multiple populations. As a subcomponent of their larger study, the authors reported that intersession variability was insignificant between days.28 However, the specific variability of sCOMP was not reported as the data were presented in a line graph figure. Our interpretation of their data was that the variability of the 5 volunteers did not differ more than 1 µg/mL, a very small difference in sCOMP levels. Notably, no documentation of participant demographics (age, gender, medical history) was provided.28 These results, in addition with our results, indicate sCOMP levels are stable and reliable between days in healthy populations.

In addition, Vilim et al.28 also reported significant differences in time point 1 (morning fasting sample) and time point 2 (2 hours after lunch) in 4 of the 20 subjects who participated in their research study. For the remaining 16 subjects in their research study, no variation in the serum samples between the time points was identified.28 It was concluded that the only differences noted for the 4 individuals were related to food consumption, and it was recommended that for future clinical research, serum draws should be performed as fasting, morning collection.28 However, the results of our study indicate strong intraday reliability, where the subjects engaged in their normal activities of daily living throughout the waking hours.29 For patients with OA, the results of the investigation revealed no significant changes in sCOMP between 09:00 and 21:00.29 However, the results of the study did reveal a significant decrease in sCOMP levels at 05:00 (P < 0.03).29 For patients with rheumatoid arthritis, no significant changes were observed between 08:00 and 20:00.29 In addition, a significant decrease in sCOMP was noted at 04:00 (P < 0.001).29 The results of this study show that sCOMP levels remain similar during the waking hours, indicating sCOMP levels can be collected throughout the day for either clinical and/or research purposes.29 Therefore, based on the results of this study and our study, the variation in sCOMP across the day is insubstantial.

A study conducted by Kong et al.30 reported diurnal variation in sCOMP in a cohort of patients with OA. The results of their clinical laboratory investigation revealed significant differences in sCOMP levels measured between the time before arising from bed (T0) and 1 hour after rising from bed (T1, P < 0.001), between T0 and 4 hours after arising from bed (T2, P < 0.001), and between T0 and 12 hours of daily activity (T3, P < 0.01).30 It must be noted the authors reported they did not allow the participants to remain seated for more than 30 minutes at a time during study participation, and subjects were encouraged to engage in activities of daily living throughout the study duration.30 Based on the recommendations of Andersson et al.23 and Mundermann et al.,24 30 minutes of rest prior to serum collection is necessary to ensure elevations in sCOMP levels are not due to any moderate exercise, such as walking to the data collection site. However, it must be noted that the results reported by Kong et al.30 would have not been privy to the effect of exercise on sCOMP levels as their study published at the same time as the results of the Mundermann et al.24 and Andersson et al.23 studies, which indicated exercise and activities of daily living have a direct effect on sCOMP levels. Our methods required the subjects to remain seated for 30 minutes prior to serum collection. We believe the addition of this resting time is necessary in order to provide the most valid results of sCOMP levels.

We did not limit the amount of physical activity each of the subjects engaged in while participating in this study. Also, our subjects’ meal times were not regulated, as the subjects were encouraged to engage in their normal activities of daily living while participating in our research study. Therefore, our results indicate this biomarker is highly reliable even when the subjects are not in a research laboratory environment where exercise, meal times, and sleeping habits are regulated.29,30

Our study is not without limitations. In order to be included in our research investigation, the subjects had to have no history of lower extremity surgery and no current acute lower extremity injury. Subjects were not given a physical examination or radiographic examination prior to study inclusion. Therefore, we were unable to verify each of the subjects were completely free of joint damage, such as OA. However, these were relatively young and active participants who reported no history of serious knee joint injury. Based on this, it is unlikely that substantial knee cartilage degradation had occurred in any of our participants.

Conclusion

Our results indicate strong interday and intraday reliability for sCOMP values in a healthy, physically active cohort with no history of lower extremity surgery. The strong reliability of this measure demonstrates serum samples can be collected throughout the day for future clinical research studies.29 The importance of these findings is that sCOMP levels are stable in an uninjured sample, and measurable increases are likely due to injury and not interday or intraday fluctuation. Our MDC95% values suggest that a change in sCOMP levels of 290 to 320 ng/mL in an injured population represents a meaningful change that exceeds the variability associated
with the measure. Future research studies are needed to further investigate the magnitude of change in this biomarker for patients with acute articular cartilage damage to determine its appropriateness for use in this population and for varying degrees of articular cartilage severity.

Acknowledgments and Funding
The authors thank the associate dean of research, College of Health Sciences, University of Kentucky, for funding their research through the College of Health Sciences Pilot Study Grant Mechanism. They also thank the University of Kentucky CR-DOC laboratory and Ken Westberry for completing the ELISAs. Finally, they thank Matthew R. Luckett, MD, for his assistance in collecting the serum samples. This research study was supported by the College of Health Sciences Pilot Study Grant Mechanism.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the authorship and/or publication of this article.

References
1. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins: an acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem. 1992;267(9):6132-6.
2. Muller G, Michel A, Altenburg E. COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. Conn Tissue Res. 1998;39(4):233-44.
3. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum. 1998;41(6):997-1006.
4. Jordan JM, Luta G, Stabler M, Renner JB, Dragomir AD, Vilim V, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum. 2003;48(3):675-81.
5. Cibere J, Zhang H, Gamero P, Poole AR, Lobanok T, Saxne T, et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009;60(5):1372-80.
6. Fernandez FA, Pucinelli MLC, da Silva NP, Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation. Scand J Rheumatol. 2007;36(3):211-5.
7. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 1999;42(11):2356-64.
8. Mundermann A, King KB, Smith RL, Andriacci TP. Change in serum COMP concentration due to ambulatory load is not related to knee OA status. J Orthop Res. 2009;27(11):1408-13.
9. Wakitani S, Nawata M, Kawaguchi A, Okabe T, Takaoka K, Tsuchiya T, et al. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology. 2007;46(11):1652-6.
10. Senolt L, Braun M, Olejarova M, Forejtova S, Gatterova J, Pavelka K. Increased pentosidase, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis. 2005;64(6):886-90.
11. Kuhne SA, Neidhart M, Everson MP, Hantschel H, Fine PR, Gay S, et al. Persistent high serum levels of cartilage oligomeric matrix protein in a subgroup of patients with traumatic knee injury. Rheumatol Int. 1998;18(1):21-5.
12. Lohmander LS, Saxne T, Heinegard DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis. 1994;53(1):8-13.
13. Dahlberg L, Roos H, Saxne T, Heinegard D, Larke MW, Hoermer LA, et al. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann Rheum Dis. 1994;53(12):823-7.
14. Rosen MA, Jackson DW, Berger PE. Occult osseous lesions documented by magnetic resonance imaging associated with anterior cruciate ligament ruptures. Arthroscopy. 1991;7(1):45-51.
15. Speer KP, Spritzer CE, Bassett FH 3rd, Feagin JA, Jr., Garrett WE Jr. Osseous injury associated with acute tears of the anterior cruciate ligament. Am J Sports Med. 1992;20(4):382-9.
16. Vellet AD, Marks PH, Fowler PJ, Munro TG. Occult posttraumatic osteochondral lesions of the knee: prevalence, classification, and short-term sequelae evaluated with MR imaging. Radiology. 1991;178(1):271-6.
17. Lynch TC, Crues JV 3rd, Morgan FW, Sheehan WE, Harter LP, Ryu R. Bone abnormalities of the knee: prevalence and significance at MR imaging. Radiology. 1989;171(3):761-6.
18. Mink JH, Deutsch AL. Occult cartilage and bone injuries of the knee: detection, classification, and assessment with MR imaging. Radiology. 1989;170(3 Pt 1):823-9.
19. Lahm A, Erggelet C, Steinwachs M, Reichelt A. Articular and osseous lesions in recent ligament tears: arthroscopic changes compared with magnetic resonance imaging findings. Arthroscopy. 1998;14(6):597-604.
20. Johnson D, Urban W, Carbond D, Vanathos W, Carlson C. Articular cartilage changes seen with magnetic resonance imaging-detected bone bruises associated with acute anterior cruciate ligament rupture. Am J Sports Med. 1998;26(3):409-14.
21. Fang C, Johnson D, Leslie MP, Carlson CS, Robbins M, Di Cesare PE. Tissue distribution and measurement of cartilage oligomeric matrix protein in patients with magnetic resonance imaging-detected bone bruises after acute anterior cruciate ligament tears. J Orthop Res. 2001;19(4):634-41.
22. Wier LT, Ayers GW, Jackson A, Rossum A, Carlos Poston W, Foreyt J. Determining the amount of physical activity needed for long-term weight control. Int J Obes. 2001;25:613-21.
23. Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, Saxne T. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskeletal Disord. 2006;7:98.
24. Mundermann A, Dyrby CO, Andriacchi TP, King KB. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis Cartilage. 2005;13(1):34-8.

25. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.

26. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol. 2001;54:1204-17.

27. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861-73.

28. Vilim V, Vobarka Z, Vytasek R, Senolt L, Tchetverikov I, Kraus VB, et al. Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. Clinica Chimica Acta. 2003;328(1-2):59-69.

29. Andersson MLE, Petersson IF, Karlsson KE, Jonsson EN, Mansson B, Heinegard D, et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1490-4.

30. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54(8):2496-504.